Join IQVIA Biotech at the Clinical Outsourcing Group (COG) New England Meeting, taking place April 28–29, 2026 at the Boston Marriott.

COG New England brings together senior decision-makers from across New England and the broader East Coast to connect with industry thought leaders, regulators, academicians and innovative solution providers. As part of this curated program, IQVIA Biotech is proud to contribute to insightful discussions and meaningful networking designed to advance clinical development.

While attending COG New England, don’t miss our featured session on April 28 at 2:40 PM, presented by Erin Finot, Vice President, Immuno-Oncology and Cell and Gene Therapy, IQVIA Biotech:

Accelerating Early‑Stage ADC Development: Reducing White Space from First‑in‑Human to Proof‑of‑Concept

Antibody drug conjugates (ADCs) are reshaping oncology pipelines, yet early‑stage development is often hindered by operational complexity and disconnects between trial phases. This session explores how sponsors can accelerate early‑phase ADC programs by reducing drug development “white space,” aligning operational strategy with innovation, and leveraging experienced oncology site partnerships to move more efficiently from first‑in‑human studies to proof‑of‑concept.

For more information on IQVIA Biotech’s presence at COG NE or to request a meeting with us, visit our event website.